Arbor Vitae

Articles

 
If you would like to contribute an article for the news section please contact us and we will consider your suggestion.

Search Article:       Archived Articles:   Show All23 June 200823 June 200823 June 200808 May 200822 April 200804 April 200801 April 200802 March 200802 March 200802 March 200825 February 200812 February 200804 February 200818 January 200811 January 200810 January 200806 January 200828 November 200725 November 200719 November 200717 November 200716 November 200715 November 200714 November 200712 November 200711 November 200710 November 200709 November 200707 October 200705 October 200704 October 200703 October 200702 October 2007

Recent

Articles

 
Good Psychiatric PracticePosted on 23 June 2008The Royal College of Psychiatrists has recently published CR148. This document offers guidance to Members on their relationships with pharmaceutical companies and other commercial organisations.Should the drug industry work with Key Opinion LeadersPosted on 23 June 2008Part 2 of 2. Another BMJ theme issue on the relationship between healthcare professionals and pharmaceutical companies. In this articles both sides are invited to debate the issue.Key Opinion Leaders - Independent Experts of Drug Representatives in disguise?Posted on 23 June 2008Part 1 of 2 articles. Ray Moynihan challenges the nature of so-called Key opinion leaders in this interesting, if predictable, article.Right Patient, Right Medicine, Right TimePosted on 08 May 2008A newly released video from the ABPI about the contribution of the pharmaceutical industry to healthcare and research in the UK, with contributions from leading academics. Click on the link below to view.Pharmaceutical Promotion and the First AmendmentPosted on 22 April 2008A new and interesting article regarding proposed regulatory changes that may allow certain "off label" promotion of medicines in the USA.ABPI Code of Practice: Controls on the promotion of prescription medicinePosted on 04 April 2008A new article by Dr Peter Aitken explaining what the "Code of Practice" means for healthcare professionals and how they can learn more about it.Joint working with the pharmaceutical industry - Department of Health ToolkitPosted on 01 April 2008The Department of Health (UK) and the ABPI have recently published a toolkit to faciliate good practice for joint working between the NHS and pharmaceutical industry. This particular toolkit is focused on how larger scale projects could be set up between NHS/Academic organisations and pharmaceutical companies. It complements Arbor Vitae's "Partnership Tool" which is focused on the interaction at the level of the individual healthcare professional.Soft Targets: Nurses and the Pharmaceutical IndustryPosted on 02 March 2008An article exploring the relationship between nurses and pharmaceutical company sponsored education for nurses.Educating Health Professionals about Drug and Device PromotionPosted on 02 March 2008An article highlighting the lack of education available to healthcare professionals on the subject of relating to the drug or devices industry.Has the hunt for conflicts of interest gone too far?Posted on 02 March 2008A debate published in BMJ on the nature and extent of conflicts of interest in relation to interactions between healthcare professionals and the pharmaceutical industry.The Invisible Influence of Drug Company SponsorshipPosted on 25 February 2008Published in the BMJ, commentary from Ray Moniyhan about the influence of drug companies on doctors' education.The Ethics of Offshoring Clinical TrialsPosted on 12 February 2008Andrew Jack of the FT discusses the extent of the shift of clinical trials to developing countries in recent years, and the ethical implications of this trend.Best Practice Guidance for joint working between the NHS and the Pharmaceutical IndustryPosted on 04 February 2008This document sets out broad guidance as to how the NHS should work with Industry, and indeed it explicitly encourages joint working where patients might benefit. This document, however, is very much principles based and does not seek to offer practical guidance for individual partnering activities.Prescribing Costs in Primary CarePosted on 18 January 2008This report by MPs highlights the further push to generic prescribing in the UK. Interestingly, it also found that 20% of GPs admitted to being more influenced by pharmaceutical companies then by official presribing advisors. In our view, if 20% admit to being more influenced by the pharmaceutical industry, the actual number is probably much higher.Doctors and the drug industry revisitedPosted on 11 January 2008An editorial which asks whether the barriers and distrust between healthcare professionals and Industry have gone too far. This is particularly interesting because the author asking the question is Kamran Abbasi who was the Editor of the BMJ when the explosive theme issue on doctors and Industry was published in 2003. That issue of the BMJ is likely, in part, to be responsible for some of the distrust that exists today. (Apologies for the reduced quality of the PDF)A report on NICE by the Health Select CommitteePosted on 10 January 2008The House of Commons Health Select Committee publishes its findings on how effective NICE has been since its inception in 1999.Doctor takes "March of Shame" to atone for drug company paymentsPosted on 06 January 2008A BMJ article reflects on recently published article in the New York Times: "Dr Drug Rep" (which can be found in full below).PICTIF ReportPosted on 28 November 2007In 2003 the UK Government commisioned a detailled report into the competiveness of the pharmaceutical sector in th UK. This is the full report. It's output is still widely cited, and therefore it has helped determine government policy towards the pharmaceutical industry over recent years.Dr Drug RepPosted on 25 November 2007American Psychiatrist, Dr Daniel Carlat, talks about his experiences and regrets in becoming an "expert advocate" for a pharmaceutical company. RANZP Guidelines for partnering with IndustryPosted on 19 November 2007The Royal Australian and New Zealand College of Psychiatrists have published guidelines on the relationship between psychiatrists and Industry - an excellent example of guidelines on this subject from a professional association in our view.Guidelines on Phase I TrialsPosted on 17 November 2007The ABPI has issued guidance to members on the conduct of Phase I Trials in the UK.The pharmaceutical industry and psychiatry: can we work in partnership ?Posted on 16 November 2007Commerical partnership between NHS/Academia and Industry is now explicit government policy. How should healthcare professionals prepare?The Secondary use of data for medical research purposesPosted on 15 November 2007The ABPI has issues guidelines to it's members on how best to approach the use of data gained through clinical trials, and then intended for use for other purposes at a later date.Working with the drug industry - is your reputation at risk?Posted on 14 November 2007An introduction to the pros and cons of consulting to Industry, and what you need to do to prepare.The pharmaceutical industry and psychiatric research - a marriage for richer....?Posted on 12 November 2007An academics' view on the research links between Industry and Academia.Dancing with the Devil ? A personal view of psychiatry's relationship with the pharmaceutical industry.Posted on 11 November 2007A critical view of the relationship between Industry and the medical profession.Psychiatry and the pharmaceutical industry: who pays the piper?Posted on 10 November 2007A perspective on the relationship between psychiatry and the pharmaceutical industry by the Critical Psychiatry Network.A Service User view of the pharmaceutical industryPosted on 09 November 2007A mental health "service user" gives a patient view on the pharmaceutical industry.The Government Response to the Health Committee report on the Influence of the Pharmaceutical IndustryPosted on 07 October 2007Following the Health Committee report into the Influence of the Pharmaceutical Industry, the Government of the Day issued it's response. Some have argued that the response was quite favourable towards the Industry, and certainly greater collaboration between public and private sectors is encouraged throughout.The Influence of the Pharmaceutical Industry - the Health Committee reportPosted on 05 October 2007In 2004 the House of Parliament launched an investigation into the influence of the pharmaceutical industry in the UK. Although the report highlighted the benefits that a dynamic Industry has bought to the UK, many concerns were also raised, both with Industry practice, and with the MHRA.PMCPA - Code of Practice 2006Posted on 04 October 2007The PMCPA Code of Practice is the self-regulatory framework that governs promotion of medicines in the UK. Although it does not directly govern behaviours of healthcare professionals who are partnering with Industry, it is important that healthcare professionals are familiar with these regulations. In addition, any healthcare professional who wishes to complain about the promotional activity of a company could use the procedures laid out in the Code.PMCPA Code of Practice - Notes for Healthcare ProfessionalsPosted on 03 October 2007For the most part, promotion of medicines in the UK is self-regulated by the Prescription Medicines Code of Practice Authority, which operates under the auspices of the ABPI. The PMCPA have publised notes for healthcare professionals which attempts to explain the full Code of Practice.A day in the life of a pharmaceutical physicianPosted on 02 October 2007Have you ever wondered what your colleagues who left the NHS to join the pharmacetucial industry actually do? This short article gives an insight to entry-level roles for physicians in Industry.